Healthcare - Asia Tech Wire

Healthcare

03:32

                            Novo Nordisk: The U.S. Food and Drug Administration (FDA) approved Ozempic to reduce the risk of worsening kidney disease. Ozempic can be used to reduce the risk of death from heart disease.
                        
15:22

                            Pfizer agrees to pay about $60 million to settle false claims allegations
                        
                            The U.S. Department of Justice issued a statement on January 24 local time saying that Pfizer Pharmaceuticals agreed to pay $59.7463 million to resolve the following allegations: Before Pfizer acquired the company, Biohaven knowingly paid kickbacks to medical service providers to induce them to prescribe Biohaven's drug Nurtec ODT, resulting in false claims submitted to Medicare and other federal healthcare programs.
                        
07:11

                            Pfizer agrees to pay about $60 million to resolve false claims, U.S. Justice Department says
                        
                            The U.S. Department of Justice said Pfizer agreed to pay about $60 million to resolve the related false statements.
                        
22:31

                            U.S. stocks opened, with the Dow Jones Industrial Average down 0.07%, the S&P 500 Index up 0.03%, and the Nasdaq Composite Index up 0.15%. Novo Nordisk (NVO.N) rose 10.62% after clinical trials showed that its weight loss drug Amycretin can reduce weight by 22%. Meta Platforms (META.O) fell 0.19%, CEO Zuckerberg plans to significantly expand the artificial intelligence team. Nvidia (NVDA.O) rose 1%.
                        
20:47

                            Novo Nordisk shares extend gains, up 14% pre-market
                        
                            Novo Nordisk shares extended their gains, rising 14% in premarket trading.
                        
18:41

                            Novo Nordisk (NVO.N) shares rose more than 8% in pre-market trading in the U.S. as clinical trials showed its weight loss drug Amycretin reduced body weight by 22%.
                        
18:38

                            Novo Nordisk's US stock rose more than 8% before the market opened. Clinical trials showed that its weight loss drug Amycretin reduced body weight by 22%.
                        
                            Novo Nordisk's US stock rose more than 8% in pre-market trading. The company announced the results of a Phase 1b/2a clinical trial for Amycretin. Patients treated with Amycretin lost 9.7% of their body weight after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks. Based on this result, Novo Nordisk is planning to further develop Amycretin for overweight or obese adults.
                        
10:31

                            The Hong Kong stock market's biotechnology sector rose and strengthened, with WuXi AppTec (02359.HK) rising more than 5%, CanSino Biologics (06185.HK) rising more than 4%, and many stocks including Tiger Pharmaceuticals (03347.HK) and Junshi Biosciences (01877.HK) following suit.
                        
22:20

                            Jefferies: Raised Eli Lilly (LLY.N) price target from $996 to $1,020.
                        
16:12

                            At the close of Hong Kong stocks, the Hang Seng Index closed up 1.75%, the Hang Seng Tech Index closed up 2.59%, WuXi AppTec (02359.HK) closed up 7.23%, and JD.com (09618.HK) closed up 7.29%.
                        
16:10

                            Hong Kong stocks closed: Hang Seng Index rose 1.75% Hang Seng Technology Index rose 2.59%
                        
                            At the close of Hong Kong stocks, the Hang Seng Index rose 1.75%, and the Hang Seng Technology Index rose 2.59%. The pharmaceutical sector led the gains, with WuXi AppTec and JD.com rising more than 7%, Meituan and Vanke rising more than 5%, and Alibaba rising more than 4%.
                        
12:01

                            Hong Kong Stocks Midday Review: Hang Seng Index rose 2.33% and Hang Seng Technology Index rose 3.17%
                        
                            At the close of Hong Kong stocks at noon, the Hang Seng Index rose 2.33% and the Hang Seng Technology Index rose 3.17%. Pharmaceutical stocks led the gains, with JD.com and WuXi AppTec rising more than 7%, Alibaba and Meituan rising more than 6%, and WuXi Biologics rising more than 5%.
                        
09:44

                            Hong Kong-listed pharmaceutical stocks strengthened, with WuXi AppTec rising more than 5%
                        
                            Hong Kong-listed pharmaceutical stocks strengthened, with WuXi AppTec rising more than 5%, followed by WuXi Biologics, CStone Pharmaceuticals, Corning Life Sciences, and Tigermed.
                        
09:36

                            The Hong Kong stock biopharmaceutical sector rose in early trading, with WuXi AppTec (02359.HK) rising more than 5%, WuXi Biologics (02269.HK) rising more than 4%, BeiGene (06160.HK), Tiger Pharmaceuticals (03347.HK) and others following suit.
                        
18:47

                            Novo Nordisk: Phase 3 clinical trial of 7.2mg semaglutide reached the primary endpoint, with a 20.7% weight loss in 72 weeks
                        
                            On January 17, local time, Novo Nordisk announced the main results of the Phase 3b clinical trial STEP UP. In the STEP UP obesity trial, once-weekly subcutaneous injection of 7.2 mg semaglutide resulted in a 20.7% weight loss at 72 weeks and an 18.7% weight loss regardless of treatment compliance. The trial met its primary endpoint, with 7.2 mg of semaglutide demonstrating statistically significant and superior weight loss compared with placebo at week 72.
                        
1738092733
104773
3

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Trends

AI AI Tesla electric vehicle bitcoin China Tencent Chinese Company South Korea Apple

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03